The ingredient, exclusively distributed by ThreoTech LLC in Europe, has been granted approval in England, Scotland and Wales, after original applications were submitted to UK regulators in 2021.
Magtein was originally developed in 2010 to increase magnesium levels in the brain and is now used in multiple products globally. It already holds approvals in multiple markets, including EU novel food status (2024) and FDA GRAS status in the US (since 2012), as well as acceptance in countries like Canada, Japan and India.
“UK authorization and associated data protection is an exciting achievement not just for Magtein but for the broader evolution of magnesium,” Rory Lipsky, executive vice president at Magtein told NutraIngredients.
“As consumers become more focused on mental wellbeing, cognitive performance and sleep, there is a growing opportunity to bring more targeted, science-backed solutions to market.”
UK approval for Magtein unlocks five-year head start
Lipsky noted that the authorization will have specific implications for companies already working in brain health, sleep or magnesium innovation.
“UK authorization is a major step forward for Magtein’s global commercial expansion,” Lipsky said. “It allows local UK brands to immediately move from concept to launch and join in the success already seen with Magtein in the European Union.”
The five-year data protection period means that Magtein has a five-year, legally protected head start in the UK, where it will be the only widely authorized source of magnesium L-threonate, giving it strong control over pricing, partnerships and market positioning while competitors are effectively locked out.
Lipsky told NI this creates a “strong window for quality, science-led category building, while preventing unauthorized products from entering the market.”
He said it offers an opportunity for brands to build meaningful differentiation by focusing on science, storytelling and product innovation rather than price competition.
Health claims for magnesium
As it stands, health claims authorized by European Food Safety Authority (EFSA) and the FSA for magnesium are limited to nervous system, muscle health and maintaining normal psychological function.
But as Lipsky explained, many brands in the UK are increasingly moving toward ‘education-first’ communication, using ‘off pack’ methods to explain the science to show how magnesium supports brain health, sleep and stress.
“This shift toward science-backed storytelling is already happening across the category, and Magtein fits naturally into that evolution,” he said.
How does Magtein differ from other magnesium forms?
Research has shown that taking 2 g of Magtein daily for six weeks improves cognitive performance, memory, reaction time and heart rate in healthy adults, while also improving self-reported sleep.
“Magnesium is already well known, but most forms are positioned around general wellness or muscle health,” Lipsky said. “Magtein is different because it is specifically studied for its role in brain health and cognitive function, with five human clinical trials published and more on the way.”
“As consumer interest grows in areas like focus, sleep, stress resilience and healthy aging, we are seeing magnesium move from a basic mineral to a more targeted, purpose-driven solution,” Lipsky said.
Successful formats and delivery systems for magnesium
While the category is gaining depth, Lipsky expects that Magtein will be taken up quickest in single-ingredient formulations as capsules and tablets, as these tend to be the fastest markets.
Looking ahead, however, he expects to see creativity come through in alternative delivery systems like powders and sachets in combination formulations for night-time focused products, as well as hydration, nootropic and relaxation products.
He noted that other markets such as the United States and Asia have shown that success comes from making science accessible.
“Brands that have performed well with Magtein have focused on educating consumers on the connection between magnesium and brain health, positioning products around clear needs like sleep, stress and mental performance, and building trust through clinically supported ingredients,” he said.
“There has also been a clear shift toward premium, science-backed formulations, which aligns well with where the UK market is heading.”
